DETECTION AND QUANTITATION OF FUSION MRNAS IN LEUKEMIA

白血病融合 MRNAS 的检测和定量

• 批准号: 6015574
• 负责人: MARIANNA Mansfield GOLDRICK
• 金额: $ 10.34万
• 依托单位: AMBION, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6015574
• 关键词: DNA primers; cell line; diagnosis design /evaluation; diagnostic tests; fusion gene; leukemia; messenger RNA; minimal residual disease; molecular oncology; neoplasm /cancer diagnosis; neoplastic cell; nucleic acid probes; nucleic acid quantitation /detection; oligonucleotides; polymerase chain reaction

The proposed work will result in diagnostic kits and assays for rapid high throughput detection and monitoring of abnormal mRNAs associated with leukemia. Hybridization-based molecular as says will be developed for rapid characterization of translocations involved in hematologic malignancies. The ability to more rapidly determine the particular translocation involved in a patient's leukemia will permit faster initiation of therapy at the time of initial diagnosis. Sensitive quantitative methods will also be developed for assessing amplified fusion mRNAs using a novel relative quantitative RT- PCR strategy. Improved assays able to provide quantitative values for fusion mRNAs will aid clinicians in determining the most effective treatment for leukemia patients at risk for relapse. The proposed assays will have a reduced chance of generating erroneous results due to sample cross-contamination, because they will provide the requisite sensitivity needed to detect minimal residual disease without the need to use sequential exponential amplification strategies, which are highly prone to contamination. The homogenous, non- gel-based as says proposed will have a reduced cost and faster turnaround time compared to current gel-based methods, which will result in cost-savings to the healthcare system as well as benefits to the patient. PROPOSED COMMERCIAL APPLICATIONS: Kits containing reagents and protocols to identify and monitor genetic abnormalities associated with leukemia and other cancers will be developed. The kits will be marketed by Ambion for use in both research and diagnostic settings.

拟议的工作将导致诊断工具包和测定，以快速高通量检测和监测与白血病相关的异常mRNA。如所述，将开发基于杂交的分子，以快速表征涉及血液系统恶性肿瘤的易位。更快地确定患者白血病涉及的特定易位的能力将允许在初次诊断时更快地开始治疗。还将开发使用一种新型的相对定量RT-PCR策略来评估放大融合mRNA的敏感定量方法。改进的测定能够为融合mRNA提供定量值的测定方法将有助于临床医生确定对患有复发风险的白血病患者的最有效治疗。拟议的测定法将减少由于样本交叉污染而产生错误结果的机会，因为它们将提供检测最小残留疾病所需的必要敏感性，而无需使用顺序指数的扩增策略，这些策略非常容易受到污染。与当前的基于凝胶的方法相比，所提议的均质，非凝胶基于凝胶的成本和更快的周转时间将降低，这将为医疗保健系统带来成本的省钱，以及对患者的收益。拟议的商业应用：将开发包含试剂和方案的套件，以识别和监测与白血病和其他癌症相关的遗传异常。这些套件将由Ambion销售，以在研究和诊断环境中使用。